61MA.F MEDCAP AB SK-40
- Market cap
- EUR 740M
- P/E
- 30.0x
- P/B
- 4.79x
- ROE
- 16.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 61MA.F undervalued?
Graham number61MA.F trades 152.5% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MEDCAP AB SK-40 fundamental analysis
No fundamental analysis for MEDCAP AB SK-40 yet.
MEDCAP AB SK-40 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MEDCAP AB SK-40
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; and Assistive Tech including digital and physical solutions in cognition, communic…
Full company profileMEDCAP AB SK-40 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MEDCAP AB SK-40 annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 1.11B | 1.59B | 1.81B | 2.11B | 2.31B |
| Gross Profit | 677M | 927M | 1.06B | 1.24B | 1.38B |
| Operating Income | 149M | 215M | 241M | 289M | 416M |
| EBITDA | 256M | 342M | 396M | 474M | 601M |
| Net Income | 118M | 172M | 207M | 220M | 280M |
| EPS | 7.94 | 12 | 14 | 15 | 19 |
| Balance Sheet | |||||
| Total Assets | 1.43B | 1.66B | 1.99B | 2.61B | 2.80B |
| Total Liabilities | 571M | 635M | 703M | 1.15B | 1.09B |
| Shareholders' Equity | 856M | 1.02B | 1.28B | 1.45B | 1.71B |
| Cash & Short-term Investments | 236M | 188M | 370M | 370M | 273M |
| Cash Flow | |||||
| Operating Cash Flow | 85.5M | 228M | 360M | 343M | 361M |
| Capital Expenditure | 44.3M | 39.3M | 66.2M | 62.2M | 60.0M |
| Free Cash Flow | 41.2M | 189M | 294M | 281M | 301M |
| Ratios | |||||
| ROE | 13.7% | 16.8% | 16.2% | 15.1% | 16.4% |
| ROA | 8.2% | 10.4% | 10.4% | 8.4% | 10.0% |
| Net Profit Margin | 10.6% | 10.8% | 11.5% | 10.4% | 12.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
MEDCAP AB SK-40 dividends
MEDCAP AB SK-40 has not paid dividends in the last 5 fiscal years.
Who owns MEDCAP AB SK-40
- Insiders 20.91%
- Institutions 55.84%
- Public & others 23.26%
- Shares outstanding 15.0M
- Free float 14.8M
MEDCAP AB SK-40 company profile
- Company name
- MEDCAP AB SK-40
- Ticker
- 61MA.F
- ISIN
- SE0009160872
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 663
- Fiscal year end
- December
- Address
- Engelbrektsgatan 9-11, Stockholm, Sweden, 114 32
- Phone
- 46 8 34 71 10
- Website
- medcap.se/en
About MEDCAP AB SK-40
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, and buyout. It prefers to invest in Biotechnology; Life sciences; Pharmaceuticals; MedTech including healthcare equipment, software, components, and packaging solutions for life science products; and Assistive Tech including digital and physical solutions in cognition, communication, environmental control, alarms, mobility, accessibility, and orthotics. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Nordic region and Northern Europe. It typically invests between SEK25 million ($2.75 million) and SEK150 million ($16.51 million) with enterprise value SEK50 million ($5.90 million) and SEK250 million ($23.06 million) and sales value between "5 million ($5.43 million) and "25 million ($27.18 million) and EBITDA between SEK1 million ($0.11 million) and SEK50 million ($5.50 million). The firm seeks to takes both minority and majority stakes. It uses its capital and loans and makes balance sheet investments. The company was founded in 2001 and is based in Stockholm, Sweden.
MEDCAP AB SK-40 management
5- Mr. Anders DahlbergChief Executive Officer · born 1976
- Ms. Kristina EkbladChief Financial Officer · born 1974
- Mr. Anders LarnholtBusiness Area Head Specialty Pharma · born 1972
- Ms. Elisabeth WhitefieldBusiness Area Head Assistive Tech
- Mr. Lars ÅngmanInvestment Manager